Gregory Dotson

Seqirus

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. We utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection. As part of the CSL Group, we have been producing influenza vaccine in Melbourne, Australia since the 1940's. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.